![Founding member Amgen turns back on Biosimilars Forum Founding member Amgen turns back on Biosimilars Forum](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt8a307f6b61c941b9/658aef0ae0878a0407e991fd/change-direction-wildpixel.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
Amgen withdrew its membership from advocacy group The Biosimilars Forum in September after disagreeing on how best to support the US biosimilar market.
Nonprofit organization The Biosimilars Forum was setup in 2015 “to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care… [by providing] evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars,” according to its mission statement.
The founding 11 members were all, unsurprisingly, biosimilar developers. Since 2015, M&A activity and a shakeup of players – Pfizer buying Hospira, Merck KGaA divesting its portfolio, for example – had whittled membership down to nine, but now Amgen has fallen out with the other eight and left the advocacy group.
Amgen has left the Biosimilars Forum, an advocacy group it helped found in 2015, citing differences of opinion. Image: iStock/wildpixel